更新于：2024-11-21

Influenza A virus vaccine H5N1(Kitasato Daiichi Sankyo Vaccine Co., Ltd.)

更新于：2024-11-21

概要

基本信息

药物类型

预防性疫苗

别名

Adsorbed Cell Culture-Derived Influenza Vaccine H5N1、Cell-culture H5N1 flu vaccine (Daiichi Sankyo Biotech)、KIB-PCI

+ [2]

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症

流感病毒感染

非在研适应症-

原研机构

Kitasato Daiichi Sankyo Vaccine Co., Ltd.

在研机构

Kitasato Daiichi Sankyo Vaccine Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

8

项与 Influenza A virus vaccine H5N1(Kitasato Daiichi Sankyo Vaccine Co., Ltd.) 相关的临床试验

JPRN-JapicCTI-142554 / Unknown status临床2/3期

Clinical trial of KIB-PCI in healthy Japanese children

开始日期2014-05-29

申办/合作机构

Kitasato Daiichi Sankyo Vaccine Co., Ltd.

JPRN-jRCT2080222503 / Unknown status临床2/3期

Clinical trial of KIB-PCI in healthy Japanese children

开始日期2014-05-29

申办/合作机构

Kitasato Daiichi Sankyo Vaccine Co., Ltd.

JPRN-JapicCTI-132190 / Unknown status临床2期

Exploratory clinical trial of KIB-PCI in healthy Japanese children

开始日期2013-07-16

申办/合作机构

Kitasato Daiichi Sankyo Vaccine Co., Ltd.

100 项与 Influenza A virus vaccine H5N1(Kitasato Daiichi Sankyo Vaccine Co., Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Influenza A virus vaccine H5N1(Kitasato Daiichi Sankyo Vaccine Co., Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Influenza A virus vaccine H5N1(Kitasato Daiichi Sankyo Vaccine Co., Ltd.) 相关的专利（医药）

登录后查看更多信息

2

项与 Influenza A virus vaccine H5N1(Kitasato Daiichi Sankyo Vaccine Co., Ltd.) 相关的文献（医药）

2016-06-15·The Journal of Immunology2区 · 医学

Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus

2区 · 医学

Article

作者: Hemmink, Johanneke D. ; Everett, Helen E. ; Charleston, Bryan ; Bailey, Michael ; Shelton, Holly ; Morgan, Sophie B. ; Brookes, Sharon M. ; Townsend, Alain M. ; Aramouni, Mario ; Tchilian, Elma ; Porter, Emily ; Harley, Ross

AbstractInfluenza A viruses are a major health threat to livestock and humans, causing considerable mortality, morbidity, and economic loss. Current inactivated influenza vaccines are strain specific and new vaccines need to be produced at frequent intervals to combat newly arising influenza virus strains, so that a universal vaccine is highly desirable. We show that pandemic H1N1 influenza virus in which the hemagglutinin signal sequence has been suppressed (S-FLU), when administered to pigs by aerosol can induce CD4 and CD8 T cell immune responses in blood, bronchoalveolar lavage (BAL), and tracheobronchial lymph nodes. Neutralizing Ab was not produced. Detection of a BAL response correlated with a reduction in viral titer in nasal swabs and lungs, following challenge with H1N1 pandemic virus. Intratracheal immunization with a higher dose of a heterologous H5N1 S-FLU vaccine induced weaker BAL and stronger tracheobronchial lymph node responses and a lesser reduction in viral titer. We conclude that local cellular immune responses are important for protection against influenza A virus infection, that these can be most efficiently induced by aerosol immunization targeting the lower respiratory tract, and that S-FLU is a promising universal influenza vaccine candidate.

2013-04-01·Expert Review of Vaccines2区 · 医学

Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development

2区 · 医学

Review

作者: Portsmouth, Daniel ; Barrett, P. Noel ; Ehrlich, Hartmut J.

Several subtypes of influenza A viruses with pandemic potential are endemic in bird populations throughout Asia, Africa and the Middle East, and evidence suggests that these viruses are adapting to the mammalian host. As emphasized by the high mortality rate of humans infected with H5N1 viruses, this situation presents a substantial risk to global human health. The Vero cell culture platform has been used to develop whole-virus influenza vaccines that provide broad cross-clade protection against viruses with pandemic potential, at low antigen doses, without the requirement for adjuvantation. The safety and immunogenicity of these vaccines has been demonstrated in studies with more than 10,000 individuals, including healthy adult and elderly subjects, children and various risk groups. These Vero cell-derived vaccines are licensed for prepandemic and pandemic use. The Vero platform is also being explored to develop next-generation live-attenuated and recombinant vaccines.

100 项与 Influenza A virus vaccine H5N1(Kitasato Daiichi Sankyo Vaccine Co., Ltd.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
流感病毒感染	日本	Kitasato Daiichi Sankyo Vaccine Co., Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

登录后查看更多信息

转化医学

使用我们的转化医学数据加速您的研究。

登录

或

查看完整样例数据

使用我们的转化医学数据加速您的研究。

药物交易

使用我们的药物交易数据加速您的研究。

登录

或

查看完整样例数据

使用我们的药物交易数据加速您的研究。

核心专利

使用我们的核心专利数据促进您的研究。

登录

或

查看完整样例数据

使用我们的核心专利数据促进您的研究。

临床分析

紧跟全球注册中心的最新临床试验。

登录

或

查看完整样例数据

紧跟全球注册中心的最新临床试验。

批准

利用最新的监管批准信息加速您的研究。

登录

或

查看完整样例数据

利用最新的监管批准信息加速您的研究。

特殊审评

只需点击几下即可了解关键药物信息。

登录

或

查看完整样例数据

只需点击几下即可了解关键药物信息。

新药情报库｜省钱又好用！

来和芽仔聊天吧

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。

生物序列数据库

生物药研发创新

化学结构数据库

小分子化药研发创新